TransMedics Group, Inc. (NASDAQ:TMDX) Insider Anil P. Ranganath Sells 4,289 Shares

TransMedics Group, Inc. (NASDAQ:TMDX) insider Anil P. Ranganath sold 4,289 shares of the stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $152.20, for a total transaction of $652,785.80. Following the completion of the sale, the insider now directly owns 8,893 shares of the company’s stock, valued at approximately $1,353,514.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

TransMedics Group Stock Performance

NASDAQ TMDX traded up $1.04 during trading hours on Friday, hitting $162.89. The company had a trading volume of 742,292 shares, compared to its average volume of 769,601. The company has a quick ratio of 8.76, a current ratio of 9.37 and a debt-to-equity ratio of 2.67. The firm has a market cap of $5.43 billion, a P/E ratio of -476.03 and a beta of 1.99. TransMedics Group, Inc. has a fifty-two week low of $36.42 and a fifty-two week high of $171.98. The business has a fifty day simple moving average of $145.03 and a 200-day simple moving average of $113.08.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.14. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The company had revenue of $114.30 million for the quarter, compared to analysts’ expectations of $98.84 million. During the same quarter in the previous year, the company posted ($0.03) earnings per share. The business’s revenue for the quarter was up 117.7% compared to the same quarter last year. Equities analysts predict that TransMedics Group, Inc. will post 1.1 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Cantor Fitzgerald started coverage on TransMedics Group in a report on Thursday, June 6th. They issued an “overweight” rating and a $161.00 price target for the company. TD Cowen raised their target price on TransMedics Group from $130.00 to $175.00 and gave the company a “buy” rating in a report on Friday, June 7th. Stephens boosted their price target on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Piper Sandler raised their target price on TransMedics Group from $170.00 to $180.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. Finally, Morgan Stanley lifted their price target on shares of TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $166.88.

Hedge Funds Weigh In On TransMedics Group

Several hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. grew its holdings in TransMedics Group by 10.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 397,283 shares of the company’s stock worth $31,358,000 after acquiring an additional 38,951 shares during the period. Vanguard Group Inc. raised its holdings in shares of TransMedics Group by 2.8% in the 4th quarter. Vanguard Group Inc. now owns 1,865,115 shares of the company’s stock worth $147,214,000 after purchasing an additional 50,673 shares in the last quarter. Alpha DNA Investment Management LLC bought a new stake in shares of TransMedics Group in the 4th quarter worth approximately $500,000. Russell Investments Group Ltd. lifted its stake in TransMedics Group by 337,462.5% during the first quarter. Russell Investments Group Ltd. now owns 27,005 shares of the company’s stock valued at $1,997,000 after purchasing an additional 26,997 shares during the last quarter. Finally, Hsbc Holdings PLC boosted its holdings in TransMedics Group by 19.0% during the fourth quarter. Hsbc Holdings PLC now owns 41,650 shares of the company’s stock worth $3,287,000 after buying an additional 6,650 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.